@article{7a7a458150bf45329e36d12cd9f7c537,
title = "Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South Texas",
abstract = "Mexican Americans have a high prevalence of diabetes and burden of diabetes-related complications, highlighting the need for novel preventive strategies and noninvasive predictors of diabetes risk tailored to this population. Changes in the gut microbiome have the potential to predict diabetes. Here, we aimed to identify alterations in the gut microbiome associated with diabetes in the high-risk population of Mexican Americans in South Texas. Stool samples were collected from 216 subjects from the population-based Cameron County Hispanic Cohort. Among them, 75 had type 2 diabetes. Taxonomic and functional profiling of the stool samples were assessed by 16S and shotgun metagenomic sequencing, and the influence of genetic factors was explored. The gut microbiome of subjects with diabetes was enriched with proinflammatory Proteobacteria members (Enterobacteriaceae, Escherichia-Shigella) and depleted of butyrate-producing Clostridiales members (Faecalibacterium prausnitzii, Peptostreptococcaceae, and Clostridium sensu stricto 1). The accompanying metagenomic changes in subjects with diabetes suggested dysregulated amino acid metabolism, reduced galacturonate and glucuronate catabolism (correlating with Faecalibacterium prausnitzii abundance), and enriched heme biosynthesis (correlating with Enterobacteriaceae abundance). Polymorphism rs7129790 near MMP27 was strongly associated with high Proteobacteria abundance and was more frequent in this cohort and in individuals of Mexican ancestry than in Europeans. In conclusion, Mexican Americans in South Texas with diabetes display distinct gut microbiome and metagenomic signatures. These signatures may have utility in risk modeling and disease prevention in this high-risk population.",
keywords = "diabetes, diabetes, gut microbiome, health disparity, metagenome, Mexican American population",
author = "Kwan, {Suet Ying} and Sabotta, {Caroline M.} and Aron Joon and Peng Wei and Petty, {Lauren E.} and Below, {Jennifer E.} and Xiaogang Wu and Jianhua Zhang and Jenq, {Robert R.} and Hawk, {Ernest T.} and McCormick, {Joseph B.} and Fisher-Hoch, {Susan P.} and Laura Beretta",
note = "Funding Information: We thank Roc{\'i}o Uribe and her team who recruited and interviewed the CCHC participants, as well as Marcela Morris, and Hugo Soriano for CCHC laboratory and data support. We also thank Tina Chang and Miriam Ortega of the MD Anderson Cancer Center Microbiome Core Facility for their help with stool specimen processing, sequencing, and analysis. Last, we thank Valley Baptist Medical Center in Brownsville, Texas, for the space used for the CCHC Center for Clinical and Translational Science Clinical Research, and the community of Brownsville and all cohort participants who so willingly participated in this study. This study was funded by MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma grant P50 CA217674 from the National Cancer Institute (NCI), and by the Clinical and Translational Science Award grant UL1 TR000371 (Center for Clinical and Translational Sciences) from the National Center for Advancing Translational Sciences. The MD Anderson Microbiome Core Facility is supported by MD Anderson Cancer Center support grant (CCSG) P30 CA016672 from NCI. Conceptualization, S.K. and L.B. Methodology, A.J. and P.W. Formal Analysis, S.K., A.J., P.W., X.W., R.R.J., and L.B. Investigation, S.K., L.E.P., J.E.B., R.R.J., J.B.M., and S.P.F.-H. Resources, C.M.S., L.E.P., J.E.B., X.W., J.Z., J.B.M., and S.P.F.-H. Writing – original draft, S.K. and L.B. Writing – review and editing, all authors. Visualization, S.K. and L.B. Supervision, P.W., J.Z., P.A.F., E.T.H., and L.B. Funding Acquisition, J.B.M., S.P.F.-H., and L.B. Robert R. Jenq advises, owns stock in, and holds intellectual property rights with Seres. He advises and owns stock in Kaleido. He advises MaaT Pharma. Funding Information: This study was funded by MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma grant P50 CA217674 from the National Cancer Institute (NCI), and by the Clinical and Translational Science Award grant UL1 TR000371 (Center for Clinical and Translational Sciences) from the National Center for Advancing Translational Sciences. The MD Anderson Microbiome Core Facility is supported by MD Anderson Cancer Center support grant (CCSG) P30 CA016672 from NCI. Publisher Copyright: {\textcopyright} 2022 Kwan et al.",
year = "2022",
month = jun,
doi = "10.1128/msystems.00033-22",
language = "English (US)",
volume = "7",
journal = "mSystems",
issn = "2379-5077",
publisher = "American Society for Microbiology",
number = "3",
}